L1CAM

1. Intralipid decreases L1CAM in humans (Relative to saline, in women with and without PMOS) (−0.33 log2 units difference in change from baseline; FDR-adjusted p ≤ 0.029).

   “Relative to saline, Intralipid lowered L1CAM, CHL1 and KIT at 180 min”

   Human trialRelative to saline, in women with and without PMOSIntralipid infusion180 minfemales

   Prospective Proteomic Associations with Incident Type 2 Diabetes and Responses to Metabolic Stress in Women with and Without Polyendocrine Metabolic Ovarian Syndrome

   International journal of molecular sciences·Nov 4, 2026

More on Intralipid

1. L1CAM was not clearly linked with association between CAD polygenic risk score and incident coronary artery disease in humans (Participants with diabetes; mediation analysis).

   “In mediation analyses, L1CAM did not attenuate the association between CAD PRS and incident CAD.”

   HumansParticipants with diabetes; mediation analysisplasma

   Proteomics for Elucidating Genetic Pathogenesis of Coronary Artery Disease in Diabetes

   AHA Scientific Sessions 2026 abstract·Nov 2, 2026

1. CAD polygenic risk score is associated with L1CAM in humans (Participants with diabetes; replicated in UKB and ARIC) (UKB: β -0.16 (95% CI -0.23 to -0.10), p=1.83E-06; ARIC: β -0.05 (95% CI -0.08 to -0.01), p=0.005).

   “CAD PRS was significantly associated with L1CAM among participants with diabetes in both UKB and ARIC”

   HumansParticipants with diabetes; replicated in UKB and ARICplasma

   Proteomics for Elucidating Genetic Pathogenesis of Coronary Artery Disease in Diabetes

   AHA Scientific Sessions 2026 abstract·Nov 2, 2026

More on CAD polygenic risk score